Table 1.

Transition percentages by arm and the numbers of transitions from each state.

Placebo
no. subjects = 387, no. transitions = 2619
Lag			EDSS				No. row
EDSS	0–1.5	2–2.5	3–3.5	4–4.5	5–5.5	6+
0–1.5	87.0	11.2	1.1	0.7	0	0	892
2–2.5	12.5	77.2	8.7	1.0	0.6	0	795
3–3.5	3.3	17.1	65.0	13.8	0.7	0.2	457
4–4.5	1.0	1.6	16.1	69.8	9.6	1.9	311
5–5.5	0	0.9	7.1	12.5	59.8	19.6	112
6+	0	0	3.8	5.8	15.4	75	52
Oral Fingolimod 0.5mg / day
no. subjects = 806, no. transitions = 4318
Lag			EDSS				No. row
EDSS	0–1.5	2–2.5	3–3.5	4–4.5	5–5.5	6+
0–1.5	88.4	10.3	1.2	0.2	0	0	1834
2–2.5	17.7	72.8	7.8	1.5	0.3	0	1165
3–3.5	3.0	14.3	71.9	9.8	0.6	0.4	694
4–4.5	1.1	3.2	17.5	72.2	5.0	0.9	439
5–5.5	0	0.7	2.0	10.8	73.6	12.8	148
6+	0	0	0	0	26.3	73.7	38
Oral Fingolimod 1.25mg / day
no. subjects = 763, no. transitions = 3956
Lag			EDSS				No. row
EDSS	0–1.5	2–2.5	3–3.5	4–4.5	5–5.5	6+
0–1.5	89.9	9.1	1.0	0	0	0	1646
2–2.5	16.2	72.6	9.8	1.0	0.3	0.1	1102
3–3.5	3.5	20.7	64.0	10.9	0.8	0.2	605
4–4.5	0.3	3.7	17.7	71.6	6.2	0.6	356
5–5.5	0	0.5	2.3	11.9	76.1	9.2	218
6+	0	0	3.4	3.4	34.5	58.6	29
Intra-muscular injected Interferon beta-1a (Avonex) 30µg / week
no. subjects = 392, no. transitions = 1441
Lag			EDSS				No. row
EDSS	0–1.5	2–2.5	3–3.5	4–4.5	5–5.5	6+
0–1.5	85.0	13.4	1.2	0.3	0	0	641
2–2.5	25.1	57.8	13.1	3.4	0.6	0	358
3–3.5	6.0	19.7	61.5	11.5	1.3	0	234
4–4.5	0.6	5.5	13.5	73.0	6.1	1.2	163
5–5.5	0	2.3	4.5	11.4	81.8	0	44
6+	0	0	0	0	100	0	1